article · The Journal of Infectious Diseases

A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants

Shabir A. Madhi
Brad Roadcap
Antonios O. Aliprantis
Xin Cao
Radha Railkar
Jose M Novoa Pizarro
Xiaowei Zang
Julie S. Shepard
Kalpit A. Vora
Andrea Likos Krick
Andrew W. Lee
Brian M. Maas
Eric A. F. Simões
Armando Acevedo
Anushua Sinha

202434 citationsOpen accessUniversity of the Witwatersrand

Abstract

Clesrovimab was generally well tolerated and exhibited an extended half-life compared to typical IgG1 antibodies, supporting its ongoing development in late-stage trials. Clinical Trial Registration. NCT03524118.

Research topics

Respiratory viral infections research
Neonatal Respiratory Health Research
Pneumonia and Respiratory Infections

Sustainable Development Goals

3Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1093/infdis/jiae581

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.